Crestline Management LP grew its holdings in Liquidia Co. (NASDAQ:LQDA - Free Report) by 69.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 83,305 shares of the company's stock after buying an additional 34,246 shares during the period. Crestline Management LP owned 0.10% of Liquidia worth $980,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LQDA. LM Advisors LLC bought a new stake in shares of Liquidia during the 4th quarter valued at $25,948,000. Invesco Ltd. increased its position in shares of Liquidia by 2,675.0% during the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after buying an additional 674,940 shares during the period. Mirabella Financial Services LLP acquired a new position in shares of Liquidia during the 4th quarter valued at $5,880,000. Eversept Partners LP grew its position in Liquidia by 314.1% in the 4th quarter. Eversept Partners LP now owns 571,305 shares of the company's stock valued at $6,719,000 after purchasing an additional 433,356 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in Liquidia during the fourth quarter worth $2,681,000. 64.54% of the stock is owned by institutional investors.
Insider Buying and Selling at Liquidia
In related news, General Counsel Russell Schundler sold 5,964 shares of the stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $80,931.48. Following the sale, the general counsel now directly owns 570,301 shares of the company's stock, valued at approximately $7,738,984.57. This represents a 1.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Roger Jeffs sold 14,130 shares of the company's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $191,744.10. Following the completion of the transaction, the chief executive officer now directly owns 1,006,420 shares in the company, valued at $13,657,119.40. This trade represents a 1.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,138 shares of company stock valued at $450,233. Corporate insiders own 26.50% of the company's stock.
Liquidia Stock Performance
LQDA stock traded up $0.49 on Monday, reaching $15.75. The company's stock had a trading volume of 1,072,141 shares, compared to its average volume of 1,004,699. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.81. The firm has a market cap of $1.35 billion, a PE ratio of -9.66 and a beta of 0.24. The business has a fifty day simple moving average of $14.25 and a two-hundred day simple moving average of $13.18.
Liquidia (NASDAQ:LQDA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, research analysts anticipate that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on LQDA. HC Wainwright restated a "buy" rating and set a $29.00 price objective on shares of Liquidia in a report on Monday. Raymond James upped their price objective on shares of Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a research report on Friday. Needham & Company LLC reiterated a "buy" rating and issued a $25.00 target price on shares of Liquidia in a research report on Monday. Finally, Scotiabank reissued an "outperform" rating on shares of Liquidia in a research note on Monday, May 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $27.13.
Read Our Latest Report on Liquidia
About Liquidia
(
Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Featured Stories
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
